<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34791571</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study.</ArticleTitle><Pagination><StartPage>3211</StartPage><EndPage>3221</EndPage><MedlinePgn>3211-3221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05723-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Plasma exchange (PE) is used to treat a range of neurological disorders. Based on results demonstrated in Alzheimer's disease, we theorized that PE with albumin replacement (PE-A) might alter the metabolic profile of plasma and cerebrospinal fluid in patients with amyotrophic lateral sclerosis (ALS) by removing disease-inducing molecules. The aim of this study was to evaluate the effect of PE-A on disease progression in ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label, non-controlled, single-arm, prospective pilot study, 13 adults with ALS had 6&#xa0;months' treatment with PE-A 5% and 6&#xa0;months' follow-up. Primary endpoints were changes from baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score and forced vital capacity (FVC) through 48&#xa0;weeks. A post hoc analysis compared individual patient data with the expected ALSFRS-R progression slope.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median ALSFRS-R score declined throughout the study, although the rate of decline was slower than expected in seven patients at treatment end and in five patients at study end. Six patients remained in the same baseline slope progression category, and four patients improved their slope category at treatment end. Median FVC decreased significantly during the study. Treatment was well tolerated. Of 330 PE-A procedures, 0.9% were associated with potentially related adverse events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although functional impairment progressed, about two-thirds of patients showed a slower than expected rate of decline at treatment end. Most patients had unaltered (54.5%) or reduced (36.4%) ALSFRS-R slope progression at treatment end. Further evaluation of PE-A in controlled studies involving more patients is warranted.</AbstractText><AbstractText Label="EUDRACT NUMBER" NlmCategory="UNASSIGNED">2013-004842-40.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier: NCT02479802.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. mpovedano@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paipa</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barcel&#xf3;</LastName><ForeName>Miquel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Apheresis, Banc de Sang i Teixits, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xed;nguez</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragon&#xe9;s</LastName><ForeName>Maria Esperan&#xe7;a</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horrillo</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;ez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grifols Bioscience Research Group, Grifols, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02479802</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Albumin</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cognitive function</Keyword><Keyword MajorTopicYN="N">Motor dysfunction</Keyword><Keyword MajorTopicYN="N">Plasma exchange</Keyword></KeywordList><CoiStatement>M&#xf3;nica Povedano, Andr&#xe9;s Paipa, Ra&#xfa;l Dom&#xed;nguez and Sandra Ortega report no conflicts of interest. Miquel Barcel&#xf3;, Michael K. Woodward, Maria Esperan&#xe7;a Aragon&#xe9;s, Raquel Horrillo, Montserrat Costa and Antonio P&#xe1;ez are employees of Grifols, the manufacturer of Albutein&#xae;.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>7</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34791571</ArticleId><ArticleId IdType="pmc">PMC9018657</ArticleId><ArticleId IdType="doi">10.1007/s10072-021-05723-z</ArticleId><ArticleId IdType="pii">10.1007/s10072-021-05723-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH. Correction: amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J, WFN Research Group On ALS/MND A revision of the El Escorial criteria &#x2013; 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291&#x2013;292. doi: 10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9:303&#x2013;309. doi: 10.1136/jnnp.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp</ArticleId><ArticleId IdType="pubmed">19762894</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20:2818. doi: 10.3390/ijms20112818.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112818</ArticleId><ArticleId IdType="pmc">PMC6600525</ArticleId><ArticleId IdType="pubmed">31185581</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998;44:696&#x2013;699. doi: 10.1002/ana.410440419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440419</ArticleId><ArticleId IdType="pubmed">9778272</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, Mattson MP. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol. 1998;44:819&#x2013;824. doi: 10.1002/ana.410440518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440518</ArticleId><ArticleId IdType="pubmed">9818940</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Nagai R, Uchida K, Horiuchi S, Yamada S, Hirano A, Kawaguchi M, Yamamoto T, Sasaki S, Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res. 2001;917:97&#x2013;104. doi: 10.1016/s0006-8993(01)02926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0006-8993(01)02926-2</ArticleId><ArticleId IdType="pubmed">11602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. Increased lipid peroxidation in sera of ALS patients. A potential biomarker of disease burden. Neurology. 2004;62:1758&#x2013;1765. doi: 10.1212/wnl.62.10.1758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.62.10.1758</ArticleId><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Yamada S, Uchida K, Hirano A, Sakoda S, Fujimura H, Sasaki S, Iwata M, Toi S, Kawaguchi M, Yamamoto T, Kobayashi M. Accumulation of protein-bound 4-hydroxy-2-hexenal in spinal cords from patients with sporadic amyotrophic lateral sclerosis. Brain Res. 2004;1019:170&#x2013;177. doi: 10.1016/j.brainres.2004.05.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.05.110</ArticleId><ArticleId IdType="pubmed">15306251</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, Mahata J, Kilty M, Bednarz K, Bell D, Gordon PH, Hornig M, Mehrazin M, Naini A, Flint Beal M. Factor-Litvak P (2008) Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9(3):177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD. Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev. 2013;2013:408681. doi: 10.1155/2013/408681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/408681</ArticleId><ArticleId IdType="pmc">PMC3596916</ArticleId><ArticleId IdType="pubmed">23533690</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Gelpi E, Jov&#xe9; M, Mota-Martorell N, Obis &#xc8;, Portero-Otin M, Povedano M, Pujol A, Pamplona R, Ferrer I. Lipid alterations in human frontal cortex in ALS-FTLD-TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathol Appl Neurobiol. 2020 doi: 10.1111/nan.12681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12681</ArticleId><ArticleId IdType="pmc">PMC8248144</ArticleId><ArticleId IdType="pubmed">33332650</ArticleId></ArticleIdList></Reference><Reference><Citation>Saul J, Hutchins E, Reiman R, Saul M, Ostrow LW, Harris BT, Van Keuren-Jensen K, Bowser R, Bakkar N. Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2020;8:92. doi: 10.1186/s40478-020-00968-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00968-9</ArticleId><ArticleId IdType="pmc">PMC7318439</ArticleId><ArticleId IdType="pubmed">32586411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo F, Riboldi G, Salani S, Nizzardo M, Simone C, Corti S, Hedlund E. Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. Cell Mol Life Sci. 2013;71(6):999&#x2013;1015. doi: 10.1007/s00018-013-1480-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1480-4</ArticleId><ArticleId IdType="pmc">PMC3928509</ArticleId><ArticleId IdType="pubmed">24100629</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure Are we any closer to registering a new treatment? Front Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Monstad I, Dale I, Petlund CF, Sjaastad O. Plasma exchange in motor neuron disease A controlled study. J Neurol. 1979;221(1):59&#x2013;66. doi: 10.1007/BF00313170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313170</ArticleId><ArticleId IdType="pubmed">92537</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Scarlato G, Valli G, Marconi M. Plasma exchange ineffective in amyotrophic lateral sclerosis. Arch Neurol. 1980;37(8):511&#x2013;513. doi: 10.1001/archneur.1980.00500570059009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1980.00500570059009</ArticleId><ArticleId IdType="pubmed">7417042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelemen J, Hedlund W, Orlin JB, Berkman EM, Munsat TL. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis. Arch Neurol. 1983;40(12):752&#x2013;753. doi: 10.1001/archneur.1983.04050110070012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1983.04050110070012</ArticleId><ArticleId IdType="pubmed">6625990</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (2015) Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf. Accessed 3 May 2021</Citation></Reference><Reference><Citation>Cortese I, Cornblath DR. Therapeutic plasma exchange in neurology: 2012. J Clin Apher. 2013;28:16&#x2013;19. doi: 10.1002/jca.21266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21266</ArticleId><ArticleId IdType="pmc">PMC3615701</ArticleId><ArticleId IdType="pubmed">23420591</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;inez-Andr&#xe9;s JM, Gasc&#xf3;n-Gim&#xe9;nez F, Coret-Ferrer F, Casanova-Estruch B, Santonja JM. Recambio plasm&#xe1;tico terap&#xe9;utico: aplicaciones en neurolog&#xed;a [Therapeutic plasma exchange: applications in neurology] Rev Neurol. 2015;60:120&#x2013;131. doi: 10.33588/rn.6003.2014393.</Citation><ArticleIdList><ArticleId IdType="doi">10.33588/rn.6003.2014393</ArticleId><ArticleId IdType="pubmed">25624088</ArticleId></ArticleIdList></Reference><Reference><Citation>Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34:171&#x2013;354. doi: 10.1002/jca.21705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21705</ArticleId><ArticleId IdType="pubmed">31180581</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamshidian A, Abd-Nikfarjam B, Khademi Z, Shaygannejad V, Salehi M. Therapeutic plasma exchange may adjust IL-6 and TGF-&#x3b2; signals in relapsed MS patients peripheral blood. J Clin Apher. 2020;35:72&#x2013;78. doi: 10.1002/jca.21755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.21755</ArticleId><ArticleId IdType="pubmed">31899560</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano CS, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005;57:787&#x2013;796. doi: 10.1080/15216540500404093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15216540500404093</ArticleId><ArticleId IdType="pubmed">16393781</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008;582:1783&#x2013;1787. doi: 10.1016/j.febslet.2008.04.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.04.057</ArticleId><ArticleId IdType="pubmed">18474236</ArticleId></ArticleIdList></Reference><Reference><Citation>Prajapati KD, Sharma SS, Roy N. Current perspectives on potential role of albumin in neuroprotection. Rev Neurosci. 2011;22:355&#x2013;363. doi: 10.1515/RNS.2011.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/RNS.2011.028</ArticleId><ArticleId IdType="pubmed">21591907</ArticleId></ArticleIdList></Reference><Reference><Citation>Gum ET, Swanson RA, Alano C, Liu J, Hong S, Weinstein PR, Panter SS. Human serum albumin and its N-terminal tetrapeptide (DAHK) block oxidant-induced neuronal death. Stroke. 2004;35:590&#x2013;595. doi: 10.1161/01.STR.0000110790.05859.DA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000110790.05859.DA</ArticleId><ArticleId IdType="pubmed">14726550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LJ, Xue YQ, Yang C, Yang WH, Chen L, Zhang QJ, Qu TY, Huang S, Zhao LR, Wang XM, Duan WM. Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo. PLoS ONE. 2012;7:e41226. doi: 10.1371/journal.pone.0041226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041226</ArticleId><ArticleId IdType="pmc">PMC3398951</ArticleId><ArticleId IdType="pubmed">22815976</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada M, Ortiz P, Anaya F, Hern&#xe1;ndez I, Mu&#xf1;oz J, N&#xfa;&#xf1;ez L, Olazar&#xe1;n J, Roca I, Cuberas G, T&#xe1;rraga L, Buendia M, Pla RP, Ferrer I, P&#xe1;ez A. Amyloid-targeted therapeutics in Alzheimer&#x2019;s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect. 2009;22:325&#x2013;339. doi: 10.1358/dnp.2009.22.6.1395256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dnp.2009.22.6.1395256</ArticleId><ArticleId IdType="pubmed">19771322</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada M, Anaya F, Ortiz P, Olazar&#xe1;n J, Shua-Haim JR, Obisesan TO, Hern&#xe1;ndez I, Mu&#xf1;oz J, Buendia M, Alegret M, Lafuente A, T&#xe1;rraga L, N&#xfa;&#xf1;ez L, Torres M, Grifols JR, Ferrer I, Lopez OL, P&#xe1;ez A. Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-&#x3b2; concentrations and cognition outcomes in Alzheimer&#x2019;s disease patients: a multicenter, randomized, controlled clinical trial. J Alzheimers Dis. 2017;56:129&#x2013;143. doi: 10.3233/JAD-160565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160565</ArticleId><ArticleId IdType="pmc">PMC5240541</ArticleId><ArticleId IdType="pubmed">27911295</ArticleId></ArticleIdList></Reference><Reference><Citation>Boada M, Lopez O, Olazaran J, Nunez L, Pfeffer M, Paricio M, Lorites J, Pi&#xf1;ol-Ripoll G, G&#xe1;mez J, Anaya F, Kiprov D, Lima J, Grifols C, Torres M, Costa M, Bozzo J, Szczepiorkowski ZM, Hendix S, Paez A. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer&#x2019;s disease: primary results of the AMBAR Study. Alzheimer&#x2019;s Dement. 2020;16:1412&#x2013;1425. doi: 10.1002/alz.12137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12137</ArticleId><ArticleId IdType="pmc">PMC7984263</ArticleId><ArticleId IdType="pubmed">32715623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169:13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, Strutt AM, Murphy J, Schulz PE, Katz JS. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS) Amyotroph Lateral Scler. 2010;11:303&#x2013;311. doi: 10.3109/17482961003727954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003727954</ArticleId><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(Suppl 3):16&#x2013;21. doi: 10.1007/BF03161085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161085</ArticleId><ArticleId IdType="pubmed">10631656</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61&#x2013;70. doi: 10.2147/DNND.S135748.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S135748</ArticleId><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. Am J Manag Care. 2018;24(15 Suppl):S327&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holm&#xf8;y T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:471&#x2013;474. doi: 10.1080/21678421.2017.1369125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, Lynch C, Pender N, Hardiman O. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83(1):102&#x2013;108. doi: 10.1136/jnnp-2011-300188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooley SC (2014) ALS-CBS manual instructions &#x2013; revised. 2014. https://www.slideshare.net/thealsassociation/als-cbs-manual-instructions-revised Accessed 3 May 2021</Citation></Reference><Reference><Citation>Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, O'Brien C, Phukan J, Lynch C, Pender N, Hardiman O. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597. doi: 10.1212/WNL.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara S, Amisaki T. Fatty acid binding to serum albumin: molecular simulation approaches. Biochim Biophys Acta. 2013;1830:5427&#x2013;5434. doi: 10.1016/j.bbagen.2013.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2013.03.032</ArticleId><ArticleId IdType="pubmed">23567799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker LA, Schr&#xf6;der CD, van Es MA, Westers P, Visser-Meily JMA, van den Berg LH. Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017;264:1413&#x2013;1420. doi: 10.1007/s00415-017-8538-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8538-4</ArticleId><ArticleId IdType="pmc">PMC5502060</ArticleId><ArticleId IdType="pubmed">28608303</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of sodium phenylbutyrate&#x2013;taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Pilot study to evaluate the efficacy and safety of plasma exchange with Albutein&#xae; 5% in patients with amyotrophic lateral sclerosis.&#xa0;https://clinicaltrials.gov/ct2/show/NCT02872142.&#xa0;Accessed 12 Nov 2021</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>